Fujifilm Focuses on Pharma

With film fading into the background, the company wants to apply its production expertise and nanotechnology techniques to drugmaking
President and CEO of Japan's Fuji Photo Film, Shigetaka Komori. Getty Images

Shigetaka Komori isn't one for subtleties. When the president and chief executive of Fujifilm Holdings (FUJI) announced, in mid-February, that his company would pay nearly $1.5 billion for a majority stake in Japanese pharmaceutical maker Toyama Chemical, he quickly established that this was no mere trophy purchase. "We aim to become a comprehensive health-care company," he boasted to reporters in Tokyo.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.